SEARCH

SEARCH BY CITATION

Targeted therapies are being assessed in castrate-resistant prostate cancer, but their development is slow, and the correct targets are not always clear. Given the propensity for prostate cancer to metastasize to bone, therapies that target the bone microenvironment are a logical choice.